Solid Tumor Targeting CAR-T Development Services by Targeting Metabolic Pathway

Metabolic reprogramming modulates energy and biomolecule metabolism within the tumor microenvironment, effectively alleviating T cell exhaustion while enhancing proliferative capacity and cytotoxic activity, thereby improving the persistence and therapeutic efficacy of CAR-T cells in solid tumors. Creative Biolabs' solid tumor targeting CAR-T development services by targeting metabolic pathway are dedicated to optimizing CAR-T cell function and adaptability through precise intervention in key metabolic circuits. Leveraging cutting-edge metabolic research and strategies, we systematically remodel the metabolic profile of CAR-T cells to bolster their survival and anti-tumor potency in the suppressive tumor milieu.

Introduction

Metabolic pathways play a pivotal role in determining the efficacy and persistence of CAR-T cell immunotherapy, as they directly influence T cell differentiation, memory formation, and resistance to exhaustion. It has been reported that the synergistic induction of autophagy and mitophagy through GLP-1 receptor signaling and Urolithin A-mediated LC3 maturation effectively rejuvenates mitochondrial metabolism, thereby enhancing CAR-T cell durability and anti-tumor function under repeated antigen exposure. Targeting metabolic pathways represents a strategic avenue to overcome the immunosuppressive tumor microenvironment (TME) and enhance T cell infiltration and persistence in solid tumors.

Fig.1 Enhancing solid tumor CAR-T persistence via metabolic intervention.¹

Solid Tumor Targeting CAR-T Development Services by Targeting Metabolic Pathway at Creative Biolabs

Creative Biolabs' Solid Tumor Targeting CAR-T Development Services by Targeting Metabolic Pathway provides a comprehensive, metabolism-focused CAR-T development platform specifically designed to overcome T cell exhaustion in solid tumors. We deliver metabolically armored CAR-T products with enhanced mitochondrial fitness and nutrient stress resistance, paired with optimized adjunct therapies and validated through physiologically relevant TME models. This integrated approach ensures superior persistence and antitumor efficacy by addressing both intrinsic T cell metabolism and extrinsic suppressive barriers.

Service Packages

Our integrated service packages provide comprehensive metabolic reprogramming solutions for solid tumor-targeting CAR-T development, addressing key challenges such as immunosuppressive metabolite accumulation and bioenergetic insufficiency to enhance T cell potency and durability within the TME.

Our Service Process

Required Starting Materials:

• CAR Construct Details: The lentiviral vector sequence, signaling domain architecture, and target antigen for your existing CAR.
• T cell Source Material: Donor source and initial expansion protocol details.
• TME Profiling Data (If Available): Information on the specific metabolic suppressor dominant in your target solid tumor type.

Key steps:

Final Deliverables:

• Metabolically Optimized CAR-T Product: Engineered, validated CAR-T cells or the final modified vector.
• Comprehensive Efficacy and Safety Data Package.

Key Advantages

• End-to-End Metabolic Checkpoint Targeting: We deliver a fully customized, one-stop solution encompassing initial metabolic profiling, target validation, and the design of combination therapy regimens, all tailored to overcome metabolic immunosuppression in solid tumors.
• Integrated TME Remodeling Strategies: Our team specializes in co-developing adjunctive treatments that concurrently disrupt key hostile factors in the TME, such as acidosis, nutrient scarcity, and immunosuppressive signals.
• Validated Combination Protocols: Each optimized CAR-T construct is accompanied by a rigorously validated adjunct therapy protocol, complete with precise dosing and sequencing guidance, to facilitate development process.

FAQs

Why Choose Us?

Creative Biolabs provides specialized CAR-T development services targeting metabolic pathways to overcome solid tumor challenges. Our unique approach integrates systems-level TME remodeling, dual-action blockade of key suppressors, and proprietary manufacturing protocols for metabolically optimized CAR-T products. These strategies collectively enhance T cell persistence, function, and efficacy within the hostile tumor microenvironment, delivering actionable solutions for next-generation cell therapies.

Customer Reviews

"During cell expansion, the utilization of Creative Biolabs' CAR-T development platform targeting metabolic pathways significantly promoted the directed differentiation of CAR-T products toward a central memory T cell phenotype with persistent memory characteristics, thereby enhancing their long-term functional persistence." Jn S*th.

"By integrating Creative Biolabs' CAR-T development strategy focused on metabolic pathways, we successfully co-developed an MCT inhibitor that effectively alleviated lactic acidosis and restored T cell proliferative capacity in a high-lactate model." Mk A*o.

"Leveraging Creative Biolabs' CAR-T development technology targeting metabolic pathways, we validated a dual-action adenosine/kynurenine blockade strategy in a triple-negative breast cancer model, which demonstrated significantly superior antitumor efficacy compared to PD-1 checkpoint inhibition alone." Ce R*z.

How to Contact Us?

We invite you to schedule a confidential consultation to explore how our specialized T cell engineering and metabolic modifier strategies can be integrated into your pipeline to enhance efficacy and accelerate your path to solid tumor victory.

Please contact our team to obtain further information and to discuss your specific project requirements.

Reference

1. Akhtar, Areej et al. "Bioengineering the metabolic network of CAR T cells with GLP-1 and Urolithin A increases persistence and long-term anti-tumor activity." Cell reports. Medicine vol. 6,3 (2025): 102021. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1016/j.xcrm.2025.102021.